Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-3.45%
|
$263,220
$214.16 P/Share
|
|
Feb 10
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,365
-6.2%
|
$506,110
$214.16 P/Share
|
|
Feb 05
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
1,930
-3.26%
|
$414,950
$215.0 P/Share
|
|
Feb 05
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
BUY
Exercise of conversion of derivative security
|
Direct |
1,930
+3.16%
|
$165,980
$86.52 P/Share
|
|
Feb 03
2021
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,453
+18.1%
|
-
|
|
Feb 03
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
1,554
-0.37%
|
$332,556
$214.25 P/Share
|
|
Feb 03
2021
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,554
+2.13%
|
$133,644
$86.52 P/Share
|
|
Feb 03
2021
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
34,778
+16.98%
|
-
|
|
Feb 03
2021
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
21,951
+27.12%
|
-
|
|
Feb 03
2021
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
44,935
+20.61%
|
-
|
|
Feb 03
2021
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
8,599
-9.98%
|
$1,848,785
$215.03 P/Share
|
|
Feb 03
2021
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
83,888
+33.43%
|
-
|
|
Feb 03
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
400
-0.23%
|
$86,400
$216.91 P/Share
|
|
Feb 03
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.69%
|
$34,400
$86.52 P/Share
|
|
Feb 03
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
BUY
Grant, award, or other acquisition
|
Direct |
30,389
+18.22%
|
-
|
|
Feb 03
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
32,077
+15.46%
|
-
|
|
Feb 03
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
BUY
Grant, award, or other acquisition
|
Direct |
20,719
+22.41%
|
-
|
|
Feb 03
2021
|
Paul M Silva SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,080
+14.3%
|
-
|
|
Feb 03
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
22,960
+21.86%
|
-
|
|
Feb 03
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,951
+25.7%
|
-
|
|
Dec 08
2020
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Bona fide gift
|
Indirect |
3,391
-31.52%
|
-
|
|
Nov 16
2020
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
38
-0.04%
|
$8,474
$223.45 P/Share
|
|
Nov 16
2020
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
7
-0.01%
|
$1,561
$223.29 P/Share
|
|
Nov 16
2020
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
91
-0.11%
|
$20,293
$223.51 P/Share
|
|
Nov 16
2020
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
42
-0.04%
|
$9,366
$223.57 P/Share
|
|
Nov 10
2020
|
Bruce I Sachs Director |
BUY
Open market or private purchase
|
Direct |
15,000
+18.83%
|
$3,255,000
$217.58 P/Share
|
|
Nov 04
2020
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
2,330
-1.65%
|
$507,940
$218.47 P/Share
|
|
Nov 04
2020
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
BUY
Exercise of conversion of derivative security
|
Direct |
2,330
+7.4%
|
$200,380
$86.52 P/Share
|
|
Nov 03
2020
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
1,553
-1.07%
|
$329,236
$212.15 P/Share
|
|
Nov 03
2020
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,553
+4.06%
|
$133,558
$86.52 P/Share
|
|
Oct 05
2020
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
10,516
-16.07%
|
$2,786,740
$265.69 P/Share
|
|
Oct 05
2020
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,729
+37.7%
|
$1,099,854
$126.68 P/Share
|